Leen Vijgen

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 6

Top Topics

Aortic Dissection

Squamous Cell Carcinoma

Respiratory Syncytial Virus

Hepatitis B Virus

Top Venues

Paediatric drugs

Health science reports

Virology journal

This page only lists publications with an associated author ORCID identifier.

Publications

Fernando Claudio Ferrero, Chien-Yu Lin, Johannes Liese, Kleber Giovanni Luz, Tatyana Stoeva, Agnes Nemeth, Manuel Gijón, Christina Calvo, Silvina Natalini Martínez, Teck-Hock Toh, Sofie Deleu, Bohang Chen, Sarah Rusch, Beatriz López Sánchez, Illse Leipoldt, Leen Vijgen, Dymphy Huntjens, Tristan Baguet, Kristi Bertzos, Mohamed Gamil, Marita Stevens, null null
CROCuS, a Phase II Study Evaluating the Antiviral Activity, Clinical Outcomes, and Safety of Rilematovir in Children Aged ≥ 28 Days and ≤ 3 Years with Acute Respiratory Tract Infection Due to Respiratory Syncytial Virus. Paediatric drugs (2024)
Fernando Claudio Ferrero, Chien-Yu Lin, Johannes Liese, Kleber Giovanni Luz, Tatyana Stoeva, Agnes Nemeth, Manuel Gijón, Christina Calvo, Silvina Natalini Martínez, Teck-Hock Toh, Sofie Deleu, Bohang Chen, Sarah Rusch, Beatriz López Sánchez, Illse Leipoldt, Leen Vijgen, Dymphy Huntjens, Tristan Baguet, Kristi Bertzos, Mohamed Gamil, Marita Stevens, null null
CROCuS, a Phase II Study Evaluating the Antiviral Activity, Clinical Outcomes, and Safety of Rilematovir in Children Aged ≥ 28 Days and ≤ 3 Years with Acute Respiratory Tract Infection Due to Respiratory Syncytial Virus. Paediatric drugs 26 (4) (2024)
Fernando Claudio Ferrero, Chien-Yu Lin, Johannes Liese, Kleber Giovanni Luz, Tatyana Stoeva, Agnes Nemeth, Manuel Gijón, Christina Calvo, Silvina Natalini Martínez, Teck-Hock Toh, Sofie Deleu, Bohang Chen, Sarah Rusch, Beatriz López Sánchez, Illse Leipoldt, Leen Vijgen, Dymphy Huntjens, Tristan Baguet, Kristi Bertzos, Mohamed Gamil, Marita Stevens, null null
CROCuS, a Phase II Study Evaluating the Antiviral Activity, Clinical Outcomes, and Safety of Rilematovir in Children Aged ≥ 28 Days and ≤ 3 Years with Acute Respiratory Tract Infection Due to Respiratory Syncytial Virus. Paediatric drugs 26 (4) (2024)
Fernando Claudio Ferrero, Chien-Yu Lin, Johannes Liese, Kleber Giovanni Luz, Tatyana Stoeva, Agnes Nemeth, Manuel Gijón, Christina Calvo, Silvina Natalini Martínez, Teck-Hock Toh, Sofie Deleu, Bohang Chen, Sarah Rusch, Beatriz López Sánchez, Illse Leipoldt, Leen Vijgen, Dymphy Huntjens, Tristan Baguet, Kristi Bertzos, Mohamed Gamil, Marita Stevens, null null
CROCuS, a Phase II Study Evaluating the Antiviral Activity, Clinical Outcomes, and Safety of Rilematovir in Children Aged ≥ 28 Days and ≤ 3 Years with Acute Respiratory Tract Infection Due to Respiratory Syncytial Virus. Paediatric drugs 26 (4) (2024)
Eric Lawitz, Fred Poordad, Julio A Gutierrez, Maria Beumont, Greet Beets, Ann Vandevoorde, Pieter Van Remoortere, Donghan Luo, Leen Vijgen, Veerle Van Eygen, Mohamed Gamil
Simeprevir, daclatasvir, and sofosbuvir for hepatitis C virus-infected patients: Long-term follow-up results from the open-label, Phase II IMPACT study. Health science reports 3 (2) (2020)
Leen Vijgen, Kim Thys, An Vandebosch, Pieter Van Remoortere, René Verloes, Sandra De Meyer
Virology analysis in HCV genotype 1-infected patients treated with the combination of simeprevir and TMC647055/ritonavir, with and without ribavirin, and JNJ-56914845. Virology journal 14 (1) (2017)